Whitehawk Therapeutics (WHWK) FCF Margin (2018 - 2025)
Whitehawk Therapeutics (WHWK) posted quarterly FCF Margin of 164.45% for Q1 2025, up 20011.0% year-over-year from N/an in Q1 2024, and up 30.28% quarter-over-quarter from 235.86% in Q4 2024.
Powered by 
Analysis
Whitehawk Therapeutics (WHWK) FCF Margin (2018 - 2025) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported FCF Margin for 7 consecutive years, with 164.45% the latest figure, recorded in Q1 2025.
- In Q1 2025, FCF Margin rose 20011.0% year-over-year to 164.45%; the TTM figure through Dec 2025 stood at 1363.65% (down 112810.0% YoY), while the FY2025 annual figure was 1363.65%, down 112810.0% from the prior year.
- FCF Margin climbed to 164.45% in Q1 2025 per WHWK's latest filing, from 235.86% in the prior quarter.
- Across five years, FCF Margin topped out at 8802.5% in Q1 2021 and bottomed at 842.57% in Q1 2022.
- Historically, FCF Margin has averaged 335.68% across 5 years, with a median of 194.68% in 2024.
- Annual changes were most pronounced in 2022 — FCF Margin slumped 964507 bps — and 2023, when it jumped 47275 bps.
- Whitehawk Therapeutics' FCF Margin stood at 85.34% in 2021, then sank by 162 bps to 223.72% in 2022, then soared by 33 bps to 150.55% in 2023, then plunged by 57 bps to 235.86% in 2024, then jumped by 30 bps to 164.45% in 2025.
- Business Quant data shows WHWK's FCF Margin at 164.45% in Q1 2025, 235.86% in Q4 2024, and 194.68% in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Whitehawk Therapeutics | 377.13 Mn | 377.13 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | -173.76% |
| Dec 31, 2024 | -210.51% |
| Sep 30, 2024 | -220.12% |
| Jun 30, 2024 | -156.95% |
| Mar 31, 2024 | -380.95% |
| Dec 31, 2023 | -165.35% |
| Sep 30, 2023 | -218.98% |
| Jun 30, 2023 | -281.31% |
| Mar 31, 2023 | -386.55% |
| Dec 31, 2022 | -217.87% |
| Sep 30, 2022 | -208.36% |
| Jun 30, 2022 | -307.27% |
| Mar 31, 2022 | -836.15% |
| Dec 31, 2021 | -88.41% |
| Mar 31, 2021 | 8,802.50% |
| Dec 31, 2020 | -22.99% |
| Sep 30, 2020 | -6,833.24% |
| Jun 30, 2020 | 68.61% |
| Dec 31, 2018 | -288,868.14% |
| Sep 30, 2018 | -33.17% |